pioglitazone has been researched along with Leukemia, Promyelocytic, Acute in 3 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Leukemia, Promyelocytic, Acute: An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The indulgent success of arsenic trioxide (ATO) in the induction of complete remission in acute promyelocytic leukemia (APL) patients has accommodated this agent into the therapeutic protocols." | 7.96 | Activation of PPARγ intensified the effects of arsenic trioxide in acute promyelocytic leukemia through the suppression of PI3K/Akt pathway: Proposing a novel anticancer effect for pioglitazone. ( Bashash, D; Esmaeili, S; Gharehbaghian, A; Hamidpour, M; Pourbagheri-Sigaroodi, A; Safaroghli-Azar, A; Salari, S, 2020) |
| "The indulgent success of arsenic trioxide (ATO) in the induction of complete remission in acute promyelocytic leukemia (APL) patients has accommodated this agent into the therapeutic protocols." | 3.96 | Activation of PPARγ intensified the effects of arsenic trioxide in acute promyelocytic leukemia through the suppression of PI3K/Akt pathway: Proposing a novel anticancer effect for pioglitazone. ( Bashash, D; Esmaeili, S; Gharehbaghian, A; Hamidpour, M; Pourbagheri-Sigaroodi, A; Safaroghli-Azar, A; Salari, S, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Esmaeili, S | 5 |
| Yousefi, AM | 3 |
| Delshad, M | 3 |
| Bashash, D | 5 |
| Safaroghli-Azar, A | 2 |
| Pourbagheri-Sigaroodi, A | 2 |
| Salari, S | 2 |
| Gharehbaghian, A | 2 |
| Hamidpour, M | 2 |
3 other studies available for pioglitazone and Leukemia, Promyelocytic, Acute
| Article | Year |
|---|---|
Synergistic effects of PI3K inhibition and pioglitazone against acute promyelocytic leukemia cells.
Topics: Apoptosis; Humans; Leukemia, Promyelocytic, Acute; Phosphatidylinositol 3-Kinases; Pioglitazone; Pro | 2023 |
Synergistic effects of PI3K inhibition and pioglitazone against acute promyelocytic leukemia cells.
Topics: Apoptosis; Humans; Leukemia, Promyelocytic, Acute; Phosphatidylinositol 3-Kinases; Pioglitazone; Pro | 2023 |
Synergistic effects of PI3K inhibition and pioglitazone against acute promyelocytic leukemia cells.
Topics: Apoptosis; Humans; Leukemia, Promyelocytic, Acute; Phosphatidylinositol 3-Kinases; Pioglitazone; Pro | 2023 |
Synergistic effects of PI3K inhibition and pioglitazone against acute promyelocytic leukemia cells.
Topics: Apoptosis; Humans; Leukemia, Promyelocytic, Acute; Phosphatidylinositol 3-Kinases; Pioglitazone; Pro | 2023 |
Synergistic effects of PI3K inhibition and pioglitazone against acute promyelocytic leukemia cells.
Topics: Apoptosis; Humans; Leukemia, Promyelocytic, Acute; Phosphatidylinositol 3-Kinases; Pioglitazone; Pro | 2023 |
Synergistic effects of PI3K inhibition and pioglitazone against acute promyelocytic leukemia cells.
Topics: Apoptosis; Humans; Leukemia, Promyelocytic, Acute; Phosphatidylinositol 3-Kinases; Pioglitazone; Pro | 2023 |
Synergistic effects of PI3K inhibition and pioglitazone against acute promyelocytic leukemia cells.
Topics: Apoptosis; Humans; Leukemia, Promyelocytic, Acute; Phosphatidylinositol 3-Kinases; Pioglitazone; Pro | 2023 |
Synergistic effects of PI3K inhibition and pioglitazone against acute promyelocytic leukemia cells.
Topics: Apoptosis; Humans; Leukemia, Promyelocytic, Acute; Phosphatidylinositol 3-Kinases; Pioglitazone; Pro | 2023 |
Synergistic effects of PI3K inhibition and pioglitazone against acute promyelocytic leukemia cells.
Topics: Apoptosis; Humans; Leukemia, Promyelocytic, Acute; Phosphatidylinositol 3-Kinases; Pioglitazone; Pro | 2023 |
Activation of PPARγ intensified the effects of arsenic trioxide in acute promyelocytic leukemia through the suppression of PI3K/Akt pathway: Proposing a novel anticancer effect for pioglitazone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Cell Cycle; Cell Line, | 2020 |
Stimulation of Peroxisome Proliferator-Activated Receptor-Gamma (PPARγ) using Pioglitazone Decreases the Survival of Acute Promyelocytic Leukemia Cells through Up-Regulation of PTEN Expression.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Discovery; Humans; Leuk | 2021 |